2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/04/17XBiotech Announces Publication of Phase 2 Data from Hidradenitis Suppurativa Phase 2 Study in The Journal of Investigative DermatologyPrinter Friendly Version
11/14/17XBiotech Announces Presentation of Novel Findings for MABp1 in the Prevention of Coronary Thrombosis at the American Heart Association Scientific SessionsPrinter Friendly Version
11/03/17XBiotech’s MABp1 to be Featured in Oral Presentation at the American Heart Association Scientific SessionsPrinter Friendly Version
10/18/17XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with OnivydeⓇ and 5-fluorouracil/folinic acid for the Treatment of Pancreatic CancerPrinter Friendly Version
10/03/17XBiotech Announces Addition of Renowned Dermatologist Dr. William Levis to its Scientific Advisory BoardPrinter Friendly Version
09/21/17XBiotech to Present at Cantor Fitzgerald’s Global Healthcare ConferencePrinter Friendly Version
09/20/17XBiotech Announces Agreement with Cedars-Sinai Medical Center to Evaluate MABp1 in Combination with OnivydeⓇ and 5-fluorouracil/folinic acid for the Treatment of Pancreatic CancerPrinter Friendly Version
09/07/17XBiotech Announces Presentation of Phase 2 Study Data Evaluating MABp1 for the Treatment of Hidradenitis SuppurativaPrinter Friendly Version
06/09/17XBiotech Announces Discontinuation of Phase III Study for Colorectal Cancer Based on Second Interim AnalysisPrinter Friendly Version
06/01/17XBiotech Presents Phase III Findings for its Antibody Therapy for Colorectal Cancer at the 2017 ASCO MeetingPrinter Friendly Version
05/30/17Dr. Razelle Kurzrock to Present Novel Biomarker Findings from XBiotech Phase III Colorectal Cancer Study Data at the 19th European Society for Medical Oncology World Congress on Gastrointestinal CancerPrinter Friendly Version
04/28/17XBiotech to Provide First Quarter 2017 Business UpdatePrinter Friendly Version
04/20/17XBiotech Announces Outcome of EMA’s Oral Explanation MeetingPrinter Friendly Version
04/10/17XBiotech Announces Additions To Its Scientific Advisory BoardPrinter Friendly Version
04/03/17XBiotech Announces Top-Line Results for 514G3 Antibody Therapy in Serious Staphylococcus aureus InfectionsPrinter Friendly Version
03/27/17XBiotech Announces On-Time Submission to the EMAPrinter Friendly Version
03/23/17XBiotech Announces Addition of Dr. Dirk Arnold to its Scientific Advisory BoardPrinter Friendly Version
03/09/17XBiotech to Provide Fourth Quarter and Full Year 2016 Business UpdatePrinter Friendly Version
03/03/17XBiotech Announces Registered Direct Offering of Common SharesPrinter Friendly Version
02/22/17XBiotech Completes Dosing of Subjects in PK Study Being Conducted in Connection with European Marketing ApplicationPrinter Friendly Version
02/21/17XBiotech Reports Affirmative Interim Analysis of Global Phase 3 Colorectal Cancer StudyPrinter Friendly Version
02/16/17XBiotech Meets Primary Endpoint in Phase 2 Study of MABp1 for Treatment of Hidradenitis Suppurativa (HS)Printer Friendly Version
01/17/17XBiotech Phase 3 Data for Colorectal Cancer Therapy is Published in The Lancet OncologyPrinter Friendly Version